Peter Hess was a reporter for Spectrum from 2019 to 2023, where he covered cannabinoids, autism prevalence, social hormones and other topics. Before joining Spectrum in 2019, he was associate science editor at Inverse, where he wrote and edited stories for a broad audience on a wide range of scientific topics, including drugs, evolution and environmental science. His work has also appeared in The Washington Post, New Scientist, Popular Science and Motherboard. Peter has an M.A. in science journalism from New York University’s Science, Health and Environmental Reporting Program. Find him on Twitter at @PeterNHess.
![Headshot of Peter Hess.](https://www.thetransmitter.org/wp-content/uploads/2023/11/Spectrum127076-2-170.jpg)
Peter Hess
Former news writer
Spectrum
From this contributor
Capturing autism’s sleep problems with devices nearable and wearable
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
![A young woman sleeps at home wearing a Dreem headband and surrounded by stuffed animals.](https://www.thetransmitter.org/wp-content/uploads/2023/06/Manoach-home-sleep-monitoring-headband-closeup-811.jpg)
Capturing autism’s sleep problems with devices nearable and wearable
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
![A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.](https://www.thetransmitter.org/wp-content/uploads/2023/01/844-going-on-trial-autism-drugs-01.jpg)
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
Swings and misses with Jeremy Veenstra-VanderWeele
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
Ruth Carper: Imaging the aging brain in autistic adults
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
![Illustration of a watch with the face taken up by an MRI scan of a brain.](https://www.thetransmitter.org/wp-content/uploads/2023/05/1200-ruth-carper-1024x683.webp)
Ruth Carper: Imaging the aging brain in autistic adults
Autism-related genes converge on microglia and dopamine in zebrafish
The findings add to the growing evidence that genes with disparate functions can play similar roles in brain development.
![Research image of zebrafish forebrains.](https://www.thetransmitter.org/wp-content/uploads/2023/05/844-lede.png)
Autism-related genes converge on microglia and dopamine in zebrafish
Explore more from The Transmitter
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
![](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200_coughingmice-1024x720.webp)
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
![Capitol building](https://www.thetransmitter.org/wp-content/uploads/2024/09/capitolhill-1200-1024x692.webp)
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
![Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200-ketamine-receptor-transmitter-neuroscience-1024x683.webp)
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.